icon-folder.gif   Conference Reports for NATAP  
 
  EASL 2024
June 5-8, Milan, Italy 		Back grey_arrow_rt.gif
 
 
 
VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels
 
 
  EASL 2024 June 5-8 Milan Italy

0611241

0611242

0611243

0611244

0611245

0611246

0611247